绝经后的激素治疗和中风风险:心脏和雌激素-孕激素替代研究 (HERS)
J A Simon1, J Hsia, J A Cauley
1General Internal Medicine Section, Medical Service, Veterans Affairs Medical Center, San Francisco, CA 94121, USA. jasimon@itsa.ucsf.edu
Circulation
|February 7, 2001
概括
雌激素加孕激素治疗没有显著改变冠状动脉疾病的绝经后妇女中风风险. 主要中风预测因素包括年龄,高血压,糖尿病,吸烟和心房动.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 神经学 神经学
背景情况:
- 观察性研究在激素治疗和中风风险方面产生了相互矛盾的结果.
- 之前没有任何临床试验研究过这种关联.
研究的目的:
- 为了研究雌激素加孕激素治疗和中风风险之间的关系.
- 分析来自心脏和雌激素-孕激素替代研究 (HERS) 的数据.
主要方法:
- 随机对照试验涉及2763名绝经后妇女.
- 结合性雌激素加孕激素与安慰剂的比较.
- 随访时间平均为4.1年,以评估中风发生率和死亡率.
主要成果:
- 激素治疗与非致命性中风,致命性中风或短暂性缺血性发作没有显著的关联.
- 确定了独立的中风预测因素:年龄增长,高血压,糖尿病,吸烟,心房动.
- 黑人女性的中风风险更高;BMI显示了相反的关联.
结论:
- 结合马类雌激素和孕激素治疗没有显著影响冠状动脉疾病的绝经后妇女中风风险.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...


